Copyright © 2005, European Society of Cardiology
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform
aDeutsches Herzzentrum and 1. Medizinische Klinik, Technische Universität, Munich, Germany
bInstitut für Experimentelle Onkologie und Therapieforschung, Technische Universität, Munich, Germany
cAnatomische Anstalt, Ludwig-Maximilians-Universität, Munich, Germany
dInstitut für Klinische Chemie, Ludwig-Maximilians-Universität, Klinikum Großhadern, Munich, Germany
eMax-Planck-Institute for Biochemistry, Munich, Germany
* Corresponding author. Tel.: +49 89 1218 1514; fax: +49 89 1218 4013. Email address: rwessely{at}dhm.mhn.de
Objective: Therapeutic strategies to provide local inhibition of mitogen mediated proliferation and migration of human coronary artery smooth muscle cells (CASMC) by means of drug-eluting stents have been shown to enable effective limitation of neointimal hyperplasia. However, currently available drug-eluting stents utilize compounds that may also adversely affect endothelial regrowth, thus possibly precipitating subsequent cardiac events. Accordingly, identification of compounds that differentially inhibit smooth muscle and endothelial cell migration and proliferation could be of substantial clinical usefulness.
Methods and results: In addition to lipid lowering, statins are known to display auxiliary pleiotropic activities. The purpose of this study was to evaluate the effect of local administration of cerivastatin on proliferation, migration and cytotoxicity of CASMC as well as coronary artery endothelial cells (CAEC) and to evaluate the effect of cerivastatin-coated stents on the inhibition of neointima formation as well as endothelial regrowth within the stented vessel. Cerivastatin displayed a differential effect on CASMC as compared to CAEC with regard to proliferation and migration; both were more profoundly inhibited in CASMC. Appreciable cytotoxicity and pro-apoptotic effects were low in both cell lines at therapeutic concentrations. Cerivastatin-elution led to significant inhibition of neointima formation in the rat carotid stent model, endothelial coverage of in-stent vascular tissue was similar with control and cerivastatin-eluting stents.
Conclusions: As proof of principle, our study provides evidence that local application of a HMG-CoA reductase inhibitor on a drug-eluting stent platform can efficiently limit neointima formation. Consequently, these compounds warrant further clinical evaluation to confirm this finding. Our data further suggest that the anti-restenotic effect of local statin administration might be associated with a more protective interaction with the endothelium than that observed with compounds currently employed on drug-eluting stents.
KEYWORDS Drug-eluting stents; Neointimal hyperplasia; Statin; Endothelium; Cell cycle
1 Present address: Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Time for primary review 27 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Fishbein, I. Alferiev, M. Bakay, S. J. Stachelek, P. Sobolewski, M. Lai, H. Choi, I. -W. Chen, and R. J. Levy Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries Circulation, April 22, 2008; 117(16): 2096 - 2103. [Abstract] [Full Text] [PDF]
|
|